Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ULTRALIFE CORP (ULBI)

Ultralife Q2 revenue dips 1.3% to $47.9 million as EPS rises to $0.15

Mixed Impact 3 of 5 earnings Written later

Ultralife reported second-quarter 2026 revenue of $47.9 million, down 1.3% from $48.6 million a year earlier, while GAAP earnings per share rose to $0.15 from $0.05. Gross margin improved to 28.9% from 23.9%, helped by a $1.1 million net IEEPA tariff refund, and backlog reached $117.5 million, which the company said is the highest in its history. The mix of a sales decline alongside higher profit makes the quarter's results mixed for shareholders.

Key points

  • Revenue was $47.9 million versus $48.6 million in Q2 2025; Battery & Energy Products sales fell 3.7% to $44.2 million, and Communications Systems sales rose 39.3% to $3.8 million.
  • GAAP EPS was $0.15 versus $0.05; adjusted EBITDA was $6.1 million versus $4.1 million.
  • Gross margin was 28.9%; excluding the $1.1 million net IEEPA refund, it was 26.6%.
  • Operating income was $3.4 million, including $0.9 million in one-time costs, versus $2.3 million a year earlier.

The filing

CompanyULTRALIFE CORP (ULBI)
Form8-K, current report
Filed with the SECAug 7, 2026, 4:01 PM ET
Accession number0001437749-26-026573

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.